ClinicalTrials.gg
CompletedNCT03409614Updated May 18, 2026Results posted

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

A Phase 3 interventional study of REGN2810 and REGN2810/chemo/ipi in Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Completed at 133 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
789
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 29
789 · median 61
Started
2018
with 3 others
Phase 3
5 of 29
2 open now
Registered
2nd of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objectives of this study are:

Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in \<50% of tumor cells.

Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.

The key secondary objectives are:

Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in \<50% of tumor cells.

Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Stage IIIB
  • Stage IIIC
  • Stage IV
  • Non-squamous NSCLC
  • Squamous NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Men and women ≥20 years of age for Japanese patients
  2. Patients with or cytologically documented squamous or non-squamous NSCLC with stage IIIB or IIIC disease who are not candidates for treatment with definitive concurrent chemoradiation or patients with stage IV disease if they have not received prior systemic treatment for recurrent or NSCLC
  3. Availability of an archival (≤5 months) or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample from a metastatic or recurrent site, which has not previously been irradiated
  4. Part 1 only: Expression of in \<50% of tumor cells determined by a commercially available assay performed by the central laboratory
  5. At least 1 radiographically by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
  6. (ECOG) performance status of ≤1
  7. Anticipated of at least 3 months

Key Exclusion Criteria:

  1. Part 1 only: Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime
  2. Active or untreated or spinal cord compression
  3. Patients with tumors tested positive for Epidermal growth factor receptor (EGFR) gene mutations, Anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase(ROS1) fusions
  4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management, or of pneumonitis within the last 5 years
  6. Ongoing or recent evidence of significant disease that required treatment with systemic treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)
  7. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
789 participants (actual)

Study arms

  • Other
    Chemo

    Part 1: Chemotherapy

    Other: Chemotherapy · Drug: Placebo

  • Experimental
    REGN2810+Chemo Part 1

    Part 1: REGN2810+chemo

    Drug: REGN2810

  • Experimental
    REGN2810+AbbrevChemo+ipi

    Part 1: REGN2810+abbrev chemo+ipi

    Drug: REGN2810/chemo/ipi

  • Experimental
    Placebo+Chemo

    Part 2: Placebo plus chemo

    Drug: Placebo

  • Experimental
    REGN2810+Chemo Part 2

    Part 2: REGN2810+chemo

    Drug: REGN2810

Interventions

  • REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2

    Also known as: cemiplimab

  • DrugREGN2810/chemo/ipi

    Drug page: Cemiplimab

    REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1

    Also known as: cemiplimab

  • OtherChemotherapy

    Platinum-based doublet chemotherapy Part 1

  • DrugPlacebo

    Matching placebo Part 2

This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Part 1: Overall Survival (OS)

    OS was defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to a maximum of 82.2 months

  2. Part 2: OS

    OS was defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to a maximum of 68.4 months

Secondary outcomes

  1. Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)

    PFS as assessed by IRC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

    Time frame: Up to a maximum of 82.2 months

  2. Part 2: PFS Per IRC

    PFS as assessed by IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

    Time frame: Up to a maximum of 68.4 months

  3. Part 1: Objective Response Rate (ORR) Per IRC

    ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).

    Time frame: Up to 32 months

  4. Part 2: ORR Per IRC

    ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a BOR of confirmed CR or PR.

    Time frame: Up to 32 months

  5. Part 1: Duration of Response (DoR)

    DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.

    Time frame: Up to 32 months

  6. Part 2: DoR

    DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.

    Time frame: Up to 32 months

  7. Part 1: Best Overall Response (BOR) Per IRC

    BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

    Time frame: Up to 32 months

  8. Part 2: BOR Per IRC

    BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

    Time frame: Up to 32 months

  9. Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

    Time frame: From first dose of study drug in Part 1, up to approximately 83 months

  10. Part 2: Number of Participants With TEAEs

    TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

    Time frame: From first dose of study drug in Part 2, up to approximately 69 months

  11. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)

    Part 1 only

    Time frame: 28 days

  12. Part 1: Number of Participants With Serious TEAEs

    Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

    Time frame: From first dose of study drug in Part 1, up to approximately 83 months

  13. Part 2: Number of Participants With Serious TEAEs

    Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

    Time frame: From first dose of study drug in Part 2, up to approximately 69 months

  14. Part 1: Number of Deaths During the On-Treatment Period

    The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

    Time frame: Up to 28 months

  15. Part 2: Number of Deaths During the On-Treatment Period

    The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

    Time frame: Up to 28 months

  16. Part 1: Estimated Survival Probability

    OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.

    Time frame: 12 months, 18 months, 24 months

  17. Part 2: Estimated Survival Probability

    OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.

    Time frame: 12 months, 18 months, 24 months

  18. Part 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

    Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 19, 20, 21, 22, 23, 24, 27, 30, 33, 36, 39, 40, 42, 45, 48, 51, 54, 57, 60, 63, 66; Follow-up visit 1 (14 to 30 days after last study treatment) then continued follow-up every 3 months

  19. Part 2: Change From Baseline in Global Health Status Score as Measured by the EORTC QLQ-C30

    The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

    Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36; Follow-up 1 (14 to 30 days after last study treatment)

07

Results

Posted Apr 29, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Started108109106312154
Randomized and treated108109103312153
Completed treatment101853702
Completed1099314
Not completed9810097281150
Withdrew: Adverse event00210
Withdrew: Death4032348342
Withdrew: Lost to follow-up22293
Withdrew: Participant decision9492521
Withdrew: Sponsor decision40050
Withdrew: Physician decision01241
Withdrew: Disease progression34493613276
Withdrew: Withdrawal of consent9710147
Withdrew: Other than specified05270
Withdrew: Non-compliance with study drug(s)00010

Outcome measures

SecondaryPart 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)

PFS as assessed by IRC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

Time frame:
Up to a maximum of 82.2 months
Reported as:
Median · months
Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)
monthsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Progression-free Survival (PFS) Per Independent Review Committee (IRC)6.5 (6.2 to 8.3)6.4 (4.2 to 8.4)6.4 (5.9 to 7.2)
Statistical analysis
  • Part 1: Cemiplimab + Chemotherapy vs Part 1: Chemotherapy · Hazard ratio (hr): 0.786 · 95% CI 0.581 to 1.065
  • Part 1: Cemiplimab+AbbrevChemo+Ipilimumab vs Part 1: Chemotherapy · Hazard ratio (hr): 0.798 · 95% CI 0.588 to 1.085
SecondaryPart 2: PFS Per IRC

PFS as assessed by IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.

Time frame:
Up to a maximum of 68.4 months
Reported as:
Median · months
Part 2: PFS Per IRC
monthsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: PFS Per IRC8.2 (6.5 to 9.0)5.5 (4.3 to 6.2)
Statistical analysis
  • Part 2: Cemiplimab + Chemotherapy vs Part 2: Placebo + Chemotherapy · Stratified Log Rank · p = <0.0001 · Hazard ratio (hr): 0.579 · 95% CI 0.467 to 0.718
SecondaryPart 1: Objective Response Rate (ORR) Per IRC

ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).

Time frame:
Up to 32 months
Reported as:
Number · Percentage of participants
Part 1: Objective Response Rate (ORR) Per IRC
Percentage of participantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Objective Response Rate (ORR) Per IRC40.7 (31.4 to 50.6)36.7 (27.7 to 46.5)28.3 (20.0 to 37.9)
Statistical analysis
  • Part 1: Cemiplimab + Chemotherapy vs Part 1: Chemotherapy · Odds ratio (or): 1.749 · 95% CI 0.985 to 3.104
  • Part 1: Cemiplimab+AbbrevChemo+Ipilimumab vs Part 1: Chemotherapy · Odds ratio (or): 1.478 · 95% CI 0.825 to 2.647
SecondaryPart 2: ORR Per IRC

ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a BOR of confirmed CR or PR.

Time frame:
Up to 32 months
Reported as:
Number · Percentage of participants
Part 2: ORR Per IRC
Percentage of participantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: ORR Per IRC43.6 (38.0 to 49.3)22.1 (15.8 to 29.5)
Statistical analysis
  • Part 2: Cemiplimab + Chemotherapy vs Part 2: Placebo + Chemotherapy · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.820 · 95% CI 1.802 to 4.415
SecondaryPart 1: Duration of Response (DoR)

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.

Time frame:
Up to 32 months
Reported as:
Median · months
Part 1: Duration of Response (DoR)
monthsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Duration of Response (DoR)7.8 (6.2 to 13.2)15.9 (8.7 to 35.1)6.2 (5.2 to 10.4)
SecondaryPart 2: DoR

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.

Time frame:
Up to 32 months
Reported as:
Median · months
Part 2: DoR
monthsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: DoR16.4 (13.1 to 19.5)7.3 (4.2 to 11.3)
SecondaryPart 1: Best Overall Response (BOR) Per IRC

BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Part 1: Best Overall Response (BOR) Per IRC
ParticipantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Complete Response (CR)352
Partial Response (PR)413528
Stable Disease (SD)414451
Progressive Disease (PD)4158
Non-CR / Non-PD301
Not Evaluable (NE)161016
SecondaryPart 2: BOR Per IRC

BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Part 2: BOR Per IRC
ParticipantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
CR200
PR11634
SD12175
PD2224
Non-CR/Non-PD31
NE3020
SecondaryPart 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

Time frame:
From first dose of study drug in Part 1, up to approximately 83 months
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)10510499
SecondaryPart 2: Number of Participants With TEAEs

TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

Time frame:
From first dose of study drug in Part 2, up to approximately 69 months
Reported as:
Count of participants · Participants
Part 2: Number of Participants With TEAEs
ParticipantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: Number of Participants With TEAEs301145
SecondaryPart 1: Number of Participants With Dose-limiting Toxicities (DLTs)

Part 1 only

Time frame:
28 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
ParticipantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)—0—
SecondaryPart 1: Number of Participants With Serious TEAEs

Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

Time frame:
From first dose of study drug in Part 1, up to approximately 83 months
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Serious TEAEs
ParticipantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Number of Participants With Serious TEAEs373722
SecondaryPart 2: Number of Participants With Serious TEAEs

Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.

Time frame:
From first dose of study drug in Part 2, up to approximately 69 months
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Serious TEAEs
ParticipantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: Number of Participants With Serious TEAEs9537
SecondaryPart 1: Number of Deaths During the On-Treatment Period

The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

Time frame:
Up to 28 months
Reported as:
Count of participants · Participants
Part 1: Number of Deaths During the On-Treatment Period
ParticipantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Number of Deaths During the On-Treatment Period362418
SecondaryPart 2: Number of Deaths During the On-Treatment Period

The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.

Time frame:
Up to 28 months
Reported as:
Count of participants · Participants
Part 2: Number of Deaths During the On-Treatment Period
ParticipantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: Number of Deaths During the On-Treatment Period8539
SecondaryPart 1: Estimated Survival Probability

OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.

Time frame:
12 months, 18 months, 24 months
Reported as:
Number · Estimated percentage of participants
Part 1: Estimated Survival Probability
Estimated percentage of participantsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
12 months59.4 (48.9 to 68.4)68.5 (58.4 to 76.6)54.0 (43.6 to 63.3)
18 months47.5 (37.2 to 57.1)51.9 (41.7 to 61.2)39.7 (29.8 to 49.4)
24 months41.0 (31.1 to 50.7)42.3 (32.4 to 51.9)26.5 (18.0 to 35.7)
SecondaryPart 2: Estimated Survival Probability

OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.

Time frame:
12 months, 18 months, 24 months
Reported as:
Number · Estimated percentage of participants
Part 2: Estimated Survival Probability
Estimated percentage of participantsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
12 months66.4 (60.8 to 71.5)53.9 (45.4 to 61.6)
18 months53.7 (47.8 to 59.2)35.8 (28.0 to 43.7)
24 months43.9 (38.2 to 49.5)27.7 (20.5 to 35.3)
SecondaryPart 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life (QoL) in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

Time frame:
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 19, 20, 21, 22, 23, 24, 27, 30, 33, 36, 39, 40, 42, 45, 48, 51, 54, 57, 60, 63, 66; Follow-up visit 1 (14 to 30 days after last study treatment) then continued follow-up every 3 months
Reported as:
Mean · Score on a Scale
Part 1: Change From Baseline in Global Health Status Score as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Score on a ScalePart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Cycle 2, Day 1 (C2D1)2.13 ± 17.2371.58 ± 15.1540.92 ± 14.930
C3D14.65 ± 16.5982.75 ± 18.3102.16 ± 16.525
C4D16.22 ± 16.5053.00 ± 20.3832.67 ± 17.446
C5D13.31 ± 19.3854.72 ± 18.4140.32 ± 18.957
C6D15.63 ± 19.3023.38 ± 19.356-1.70 ± 20.552
C9D16.87 ± 17.9651.80 ± 22.005-3.79 ± 16.399
C12D14.44 ± 22.0199.15 ± 20.650-3.57 ± 13.486
C15D17.35 ± 24.7699.40 ± 19.325-5.56 ± 13.608
C18D16.73 ± 25.60614.44 ± 20.983-3.33 ± 13.944
C19D122.62 ± 20.2504.17 ± 18.898-16.67 ± 0.000
C20D113.89 ± 26.1769.52 ± 12.199-16.67 ± 0.000
C21D111.36 ± 24.33615.71 ± 20.5920.00 ± 13.608
C22D120.00 ± 29.2265.95 ± 9.272-16.67
C23D111.67 ± 26.74512.50 ± 4.811-8.33 ± 11.785
C24D18.33 ± 26.04014.29 ± 23.295-11.11 ± 9.623
C27D18.89 ± 24.69419.05 ± 18.285-22.22 ± 41.944
C30D110.94 ± 25.40813.64 ± 17.918-5.56 ± 19.245
C33D112.82 ± 19.42914.17 ± 17.5430.00 ± 23.570
C36D112.50 ± 22.71313.24 ± 17.93616.67
C39D150.00—16.67
C40D150.00——
C42D150.00—16.67
C45D150.00——
C48D150.00——
C51D150.00——
C54D133.33——
C57D133.33——
C60D133.33——
C63D133.33——
C66D141.67——
Follow-up 14.05 ± 18.4553.14 ± 21.2603.87 ± 20.839
Follow-up 28.33 ± 11.78533.333.21 ± 22.704
Follow-up 3-8.33—4.17 ± 5.893
PrimaryPart 1: Overall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to a maximum of 82.2 months
Reported as:
Median · months
Part 1: Overall Survival (OS)
monthsPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: Chemotherapy
Part 1: Overall Survival (OS)15.9 (11.7 to 24.2)20.1 (13.7 to 28.3)13.9 (10.0 to 17.7)
Statistical analysis
  • Part 1: Cemiplimab + Chemotherapy vs Part 1: Chemotherapy · Stratified Log Rank · p = 0.1782 · Hazard ratio (hr): 0.813 · 95% CI 0.601 to 1.100
  • Part 1: Cemiplimab+AbbrevChemo+Ipilimumab vs Part 1: Chemotherapy · Hazard ratio (hr): 0.642 · 95% CI 0.472 to 0.874
PrimaryPart 2: OS

OS was defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to a maximum of 68.4 months
Reported as:
Median · months
Part 2: OS
monthsPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
Part 2: OS21.1 (15.9 to 23.9)12.9 (10.6 to 16.1)
Statistical analysis
  • Part 2: Cemiplimab + Chemotherapy vs Part 2: Placebo + Chemotherapy · Stratified Log Rank · p = 0.0002 · Hazard ratio (hr): 0.662 · 95% CI 0.531 to 0.825
SecondaryPart 2: Change From Baseline in Global Health Status Score as Measured by the EORTC QLQ-C30

The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items-"How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?"-each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a 0-100 scale; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.

Time frame:
Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36; Follow-up 1 (14 to 30 days after last study treatment)
Reported as:
Mean · Score on a Scale
Part 2: Change From Baseline in Global Health Status Score as Measured by the EORTC QLQ-C30
Score on a ScalePart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
C2D10.31 ± 17.1991.50 ± 18.190
C3D10.96 ± 17.1752.80 ± 17.098
C4D11.92 ± 19.2934.09 ± 18.592
C5D13.35 ± 18.9122.28 ± 21.686
C6D13.42 ± 19.6492.89 ± 19.452
C9D13.65 ± 19.6572.02 ± 21.236
C12D12.37 ± 19.0563.54 ± 23.862
C15D16.23 ± 18.0906.61 ± 22.091
C18D15.28 ± 21.57810.09 ± 22.323
C21D16.07 ± 21.34018.59 ± 22.088
C24D15.05 ± 20.34710.83 ± 25.474
C27D15.27 ± 21.9058.33 ± 27.003
C30D16.82 ± 19.9474.17 ± 45.896
C33D14.56 ± 20.51827.78 ± 25.459
C36D16.94 ± 21.36341.67 ± 11.785
Follow-up 1-2.70 ± 21.826-0.99 ± 23.422

Adverse events

Collected over From the time the informed consent was signed, up to approximately 83 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cemiplimab + Chemotherapy84/108 (77.8%)38/108 (35.2%)102/108 (94.4%)
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab80/109 (73.4%)39/109 (35.8%)97/109 (89%)
Part 1: Chemotherapy80/103 (77.7%)23/103 (22.3%)94/103 (91.3%)
Part 1: Chemotherapy to Cemiplimab7/31 (22.6%)7/31 (22.6%)19/31 (61.3%)
Part 2: Cemiplimab + Chemotherapy232/312 (74.4%)95/312 (30.4%)288/312 (92.3%)
Part 2: Placebo + Chemotherapy129/153 (84.3%)38/153 (24.8%)136/153 (88.9%)
Most frequent serious events
Showing 10 of 170
Most frequent serious events
EventPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 1: Chemotherapy to CemiplimabPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
PneumoniaInfections and infestations8/1083/1092/1031/319/3124/153
DeathGeneral disorders2/1080/1095/1030/319/3122/153
AnaemiaBlood and lymphatic system disorders3/1084/1094/1030/319/3123/153
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1084/1090/1030/315/3122/153
Urinary tract infectionInfections and infestations0/1081/1090/1031/311/3121/153
HaematemesisGastrointestinal disorders0/1080/1090/1031/310/3120/153
Cerebrovascular accidentNervous system disorders0/1080/1092/1031/311/3120/153
HaemothoraxRespiratory, thoracic and mediastinal disorders0/1080/1090/1031/310/3120/153
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/1082/1090/1031/310/3120/153
Immune-mediated hepatitisHepatobiliary disorders0/1080/1090/1031/310/3120/153
Most frequent other events
Showing 10 of 55
Most frequent other events
EventPart 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 1: Chemotherapy to CemiplimabPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + Chemotherapy
AnaemiaBlood and lymphatic system disorders52/10837/10939/1036/31138/31261/153
AlopeciaSkin and subcutaneous tissue disorders30/10822/10933/1030/31117/31267/153
NauseaGastrointestinal disorders25/10831/10931/1031/3179/31225/153
NeutropeniaBlood and lymphatic system disorders31/10818/10927/1030/3147/31219/153
AstheniaGeneral disorders24/10821/10914/1031/3141/31217/153
ArthralgiaMusculoskeletal and connective tissue disorders23/10820/10916/1032/3154/31221/153
FatigueGeneral disorders13/10823/10916/1031/3146/31213/153
Decreased appetiteMetabolism and nutrition disorders22/10817/10917/1031/3156/31220/153
HyperglycaemiaMetabolism and nutrition disorders9/1086/1097/1030/3158/31218/153
ThrombocytopeniaBlood and lymphatic system disorders20/10810/10914/1030/3143/31219/153

Baseline characteristics

Full Analysis Set (FAS) included all participants to whom study treatment had been assigned by randomization in each study part.

Age, Continuous
Age, Continuous(Years)Part 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + ChemotherapyTotal
Median63.0 (32 to 87)64.0 (39 to 85)63.0 (40 to 81)63.0 (25 to 82)63.0 (34 to 84)63.0 (25 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + ChemotherapyTotal
Female2116134431125
Male879393268123664
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + ChemotherapyTotal
White919791267138684
Asian1267451686
Not reported020002
Missing5480017
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Cemiplimab + ChemotherapyPart 1: Cemiplimab+AbbrevChemo+IpilimumabPart 1: ChemotherapyPart 2: Cemiplimab + ChemotherapyPart 2: Placebo + ChemotherapyTotal
Hispanic or Latino200002
Not Hispanic or Latino10110498311149763
Not reported010157
Missing5480017
08

Study locations

133 sites
  • Regeneron Research Site
    Rancho Mirage, California 92270, United States
  • Regeneron Research Site
    Riverside, California 92506, United States
  • Regeneron Research Site
    Whittier, California 90603, United States
  • Regeneron Research Site
    Orange City, Florida 32763, United States
  • Regeneron Research Site
    St. Petersburg, Florida 33709, United States
  • Regeneron Research Site
    Wichita, Kansas 67214, United States
  • Regeneron Research Site
    Bethesda, Maryland 20817, United States
  • Regeneron Research Site
    Farmington, New Mexico 87401, United States
  • Regeneron Research Site
    Gettysburg, Pennsylvania 17325, United States
  • Regeneron Research Site
    Vienna, 1130, Austria
  • Regeneron Research Site
    Baoding, 071105, China
  • Regeneron research Site
    Beijing, 100050, China
  • Regeneron Research Site
    Changsha, 410013, China
  • Regeneron Research Site
    Guangzhou, 510080, China
  • Regeneron Research Site
    Hangzhou, 310002, China
  • Regeneron Research Site
    Hangzhou, 310003, China
  • Regeneron Research Site
    Hangzhou, 310009, China
  • Regeneron Research Site
    Hangzhou, 310013, China
  • Regeneron Research Site
    Jinan, 250013, China
  • Regeneron Research Site
    Linyi, 276001, China
  • Regeneron Research Site
    Nanjing, 210003, China
  • Regeneron Research Site
    Shanghai, 200040, China
  • Regeneron Research Site
    Shanghai, 200433, China
  • Regeneron Research Site
    Shenyang, 110042, China
  • Regeneron Research Site
    Xiangyang, 441021, China
  • Regeneron Research Site
    Zhengzhou, 450003, China
  • Regeneron Research Site
    Zhengzhou, 450008, China
  • Regeneron Research Site
    Bayonne, 64100, France
  • Regeneron Research Site
    Créteil, 94010, France
  • Regeneron Research Site
    Le Mans, 72000, France
  • Regeneron Research Site
    Lille, 59037, France
  • Regeneron Research Site
    Lyon, 69310, France
  • Regeneron Research Site
    Mont-de-Marsan, 40024, France
  • Regeneron Research Site
    Saint-Herblain, 44805, France
  • Regeneron Research Site
    Saint-Mandé, 94160, France
  • Regeneron Research Site
    Strasbourg, 67091, France
  • Regeneron Research Site
    Batumi, 6000, Georgia
  • Regeneron Research Site
    Tbilisi, 0112, Georgia
  • Regeneron Research Site
    Tbilisi, 0144, Georgia
  • Regeneron Research Site #1
    Tbilisi, 0159, Georgia
  • Regeneron Research Site #2
    Tbilisi, 0159, Georgia
  • Regeneron Research Site
    Tbilisi, 0186, Georgia
  • Regeneron Research Site
    Thessaloniki, Macedonia 54645, Greece
  • Regeneron Research Site
    Athens, 11527, Greece
  • Regeneron Research Site
    Kifissia, 14564, Greece
  • Regeneron Research Site
    Larissa, 41334, Greece
  • Regeneron Research Site
    Pylaia, 57001, Greece
  • Regeneron Research Site
    Thessaloniki, 54007, Greece
  • Regeneron Research Site
    Dublin, 9, Ireland
  • Regeneron Research Site
    Limerick, V94F858, Ireland
  • Regeneron Research Site
    Cremona, 26100, Italy
  • Regeneron Research Site
    Meldola, 47014, Italy
  • Regeneron Research Site
    Milan, 20162, Italy
  • Regeneron Research Site
    Monserrato, 09042, Italy
  • Regeneron Research Site
    Piacenza, 29121, Italy
  • Regeneron Research Site
    Saronno, 21047, Italy
  • Regeneron Research Site
    Terni, 05100, Italy
  • Regeneron Research Site
    Treviglio, 24047, Italy
  • Regeneron Research Site
    Klaipėda, LT-92288, Lithuania
  • Regeneron Research Site
    Vilnius, LT-08660, Lithuania
  • Regeneron Research Site
    Kuala Lumpur, Kuala Lumpur 59100, Malaysia
  • Regeneron Research Site
    George Town, 10350, Malaysia
  • Regeneron Research Site
    Johor Bahru, 81100, Malaysia
  • Regeneron Research Site
    Kota Kinabalu, 88996, Malaysia
  • Regeneron Research Site
    Kuala Lumpur, 56000, Malaysia
  • Regeneron Research Site
    Kuala Lumpur, 59100, Malaysia
  • Regeneron Research Site
    Kuantan, 25100, Malaysia
  • Regeneron Research Site
    Pulau Pinang, 10990, Malaysia
  • Regeneron Research Site
    Tanjung Bungah, 11200, Malaysia
  • Regeneron Research Site
    Gdynia, Pomeranian Voivodeship 81-519, Poland
  • Regeneron Research Site
    Lodz, 90-302, Poland
  • Regeneron Research Site
    Lublin, 20-093, Poland
  • Regeneron Research Site
    Olsztyn, 10-357, Poland
  • Regeneron Research Site
    Otwock, 05-400, Poland
  • Regeneron Research Site
    Poznan, 60-693, Poland
  • Regeneron Research Site
    Rzeszów, 35-021, Poland
  • Regeneron Research Site
    Torun, 87-100, Poland
  • Regeneron Research Site
    Wodzisław Śląski, 44-300, Poland
  • Regeneron Research Site
    Cluj-Napoca, 400006, Romania
  • Regeneron Research Site
    Cluj-Napoca, 400124, Romania
  • Regeneron Research Site
    Craiova, 200094, Romania
  • Regeneron Research Site
    Craiova, 200347, Romania
  • Regeneron Research Site
    Craiova, 200385, Romania
  • Regeneron Research Site
    Ufa, Republic Bashkortost 450054, Russia
  • Regeneron Research Site
    Arkhangelsk, 163045, Russia
  • Regeneron Research Site
    Belgorod, 308010, Russia
  • Regeneron Research Site
    Chelyabinsk, 454048, Russia
  • Regeneron Research Site
    Kaluga, 248007, Russia
  • Regeneron Research Site
    Kazan', 420029, Russia
  • Regeneron Research Site
    Kursk, 305016, Russia
  • Regeneron Research Site
    Moscow, 115478, Russia
  • Regeneron Research Site
    Moscow, 121467, Russia
  • Regeneron Research Site
    Moscow Region, 143444, Russia
  • Regeneron Research Site
    Omsk, 644013, Russia
  • Regeneron Research Site
    Pushkin, 196603, Russia
  • Regeneron Research Site
    Pyatigorsk, 357502, Russia
  • Regeneron Research Site
    Saint Petersburg, 191104, Russia
  • Regeneron Research Site
    Saint Petersburg, 197758, Russia
  • Regeneron Research Site
    Saint Petersburg, 198255, Russia
  • Regeneron Research Site
    Samara, 443001, Russia

Showing the first 100 of 133 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Ag McIntyre D, Perez J, Kaul M, Quek RGW, Seebach F, Rietschel P, Pouliot JF. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer. 2024 Jul;193:107821. doi: 10.1016/j.lungcan.2024.107821. Epub 2024 May 13. PubMed 38820979 ↗
  • Zhao B, Qi H, Wu J, Ma W. Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jul;18(7):e72-e73. doi: 10.1016/j.jtho.2023.04.001. No abstract available. PubMed 37348996 ↗
  • Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. PubMed 37001859 ↗
  • Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25. PubMed 36008722 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Feb 2025, 83 months.

Results were first posted in Apr 2026, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 83 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Jan 24, 2018
StartActual
Mar 6, 2018
Primary completionActual
Feb 27, 2025
CompletionActual
Feb 27, 2025
Results first posted
Apr 29, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03409614
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Mar 6, 2018
Primary completion
Feb 27, 2025
Completion
Feb 27, 2025
Results posted
Apr 29, 2026
Last update
May 18, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion